Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. The company is conducting Phase Ib clinical trial of Coversin. The company focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
Website: akaritx.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), are preserved at an average historical level (0.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -35.3% (LTM)
  • Share price is 11.1% higher than minimum and 97.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: AKTX
Share price, USD:  (0.0%)0.2722
year average price 0.8751  


year start price 1.0800 2025-02-14

max close price 1.5300 2025-03-21

min close price 0.2450 2025-12-18

current price 0.2722 2026-02-13
Common stocks: 62 434 624

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 17
Net Debt ($m): -7
EV (Enterprise Value): 10
EBITDA LTM (млн $): -16
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-30globenewswire.com

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

2025-12-23globenewswire.com

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

2025-12-18globenewswire.com

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

2025-12-09globenewswire.com

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

2025-11-18seekingalpha.com

Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript

2025-11-18globenewswire.com

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

2025-10-30globenewswire.com

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

2025-09-10seekingalpha.com

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

2025-08-14globenewswire.com

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

2025-07-29globenewswire.com

Akari Therapeutics Releases Virtual Investor “What This Means” Segment
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2022 q4 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-19 2024-08-19 2024-03-31 2023-09-30 2023-09-29 2022-09-27 2022-05-17
acceptedDate 2025-11-13 17:01:14 2025-08-13 17:01:23 2025-04-15 16:33:07 2024-11-19 16:48:29 2024-08-19 16:30:27 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-09-28 20:00:00 2023-09-29 08:01:40 2022-12-31 00:00:00 2022-09-27 16:30:48 2022-05-17 16:30:36 2022-05-16 06:04:17 2021-04-20 18:33:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 FY Q2 Q1 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 12 999 0 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 -12 999 0 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 247 504 667 000 7M 143 000 3M 2M 8M 4M 1627.611 10M 3M 2M 9M 12M
generalAndAdministrativeExpenses 0 2M 10M 2M 2M 3710 11M 3M 2977.19 14M 3M 3M 8M 9M
sellingAndMarketingExpenses 0 0 0 0 0 4M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 2M 10M 2M 2M 4M 11M 3M 2977.19 14M 3M 3M 8M 9M
otherExpenses 0 0 5M 1M 0 -2 -3M 0 0 0 -9205 -7109 0 -3M
operatingExpenses 2M 3M 22M 3M 6M 6M 17M 4M 1528.85 23M 6M 5M 17M 18M
costAndExpenses 2M 3M 22M 3M 7M 6M 17M 4M 1528.85 23M 6M 5M 17M 18M
interestIncome 993.994 0 8000 3000 2000 2 82 000 0 29.546 45 944 3955 4362 10 600 13 000
interestExpense 120 273 50 000 -244 000 69 000 51 000 0 0 0 0 0 3955 -67 590 0 0
depreciationAndAmortization 0 0 14 000 101 000 -58 000 12 999 4000 1075 0.925 4000 -140 482 -69 331 4126 8907
ebitda -7M -2M -20M -3M -8M -6M -17M -4M -4603.875 -23M -6M -5M -17M -18M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -2M -3M -22M -3M -7M -6M -17M -4M -4604.8 -23M -6M -5M -17M -18M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -5M 1M 2M 32 000 -109 000 423 000 7M 293 504 3105.496 5M 136 174 67 590 -210 101 899 357
incomeBeforeTax -7M -2M -20M -3M -8M -6M -10M -4M -1499.304 -18M -6M -5M -17M -17M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense -1M 0 0 0 0 1 0 0 -0 0 -136 174 -67 590 0 0
netIncome -6M -2M -20M -3M -8M -6M -10M -4M -1499.304 -18M -6M -5M -17M -17M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -19 480 -120.4 -1660 -0.24 -0.8 -0.83 -200 -0.65 -0.34 -220 -0.093 -0.095 -820 -1560
epsdiluted -19 480 -120.4 -0.24 -0.8 -0.83 -0.65 -0.34 -0.093 -0.095
weightedAverageShsOut 326 15 735 11 944 12M 9M 7M 4894 5M 4393 3121 59M 54M 2146 1122
weightedAverageShsOutDil 326 15 735 11 944 12M 9M 7M 4894 5M 4393.669 3121 59M 54M 2146 1579
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-04-15 2023-12-31 2022-12-31 2022-05-16 2021-04-21
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 252 000 82 000 45 944 10 600 13 000
ebit -20M -17M -23M -17M -18M
nonOperatingIncomeExcludingInterest -2M 0 0 0 0
netIncomeFromContinuingOperations -20M -10M -18M -17M -17M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -20M -10M -18M -17M -17M
epsDiluted -1660 -200 -220 -820 -1120

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-11-08 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-19 2024-08-19 2024-03-31 2023-09-30 2023-09-29 2023-03-31 2022-11-08 2022-06-30 2022-03-31
acceptedDate 2025-11-13 17:01:14 2025-08-13 17:01:23 2025-04-15 16:33:07 2024-11-19 16:48:29 2024-08-19 16:30:27 2024-03-29 20:00:00 2024-03-29 14:15:41 2023-09-28 20:00:00 2023-09-29 08:01:40 2023-03-31 10:31:58 2023-04-28 15:29:46 2022-11-08 16:34:28 2022-06-29 20:00:00 2022-03-30 20:00:00 2022-05-16 06:04:17 2021-04-20 18:33:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 2M 3M 3M 2M 4M 1M 4M 4M 7M 0 13M 0 8M 17M 9M 14M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 2M 3M 3M 2M 4M 1M 4M 4M 7M 0 13M 0 8M 17M 9M 14M
netReceivables 0 0 201 000 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 462 000 590 000 60 000 488 000 899 000 1M 197 000 496 000 186 566 0 100 000 0 3M 3M 90 301 229 200
totalCurrentAssets 3M 3M 3M 3M 5M 3M 4M 4M 8M 0 14M 0 11M 19M 12M 15M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwill 8M 8M 8M 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 34M 39M 39M 0 0 0 14 000 14 000 15 779 0 17 000 0 18 844 21 335 22 929 27 150
goodwillAndIntangibleAssets 42M 48M 48M 0 0 0 14 000 14 000 15 779 0 17 000 0 18 844 21 335 22 929 27 150
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalNonCurrentAssets 42M 48M 48M 0 0 0 14 000 14 000 15 779 0 17 000 0 18 844 21 335 22 929 27 150
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 45M 51M 51M 3M 5M 3M 4M 4M 8M 0 14M 0 11M 19M 12M 15M
accountPayables 11M 12M 12M 5M 5M 3208 2M 2M 1M 0 947 000 0 2M 3M 2M 3M
shortTermDebt 2M 2M 3M 1 000 000 1 000 000 0 0 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 3M 4M 2M 4M 3M 6M 3M 3M 4M 0 8M 0 1M 2M 1M 0
totalCurrentLiabilities 16M 17M 20M 9M 9M 6M 5M 5M 5M 0 12M 0 3M 6M 6M 5M
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 7M 8M 8M 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 169 000 128 000 383 000 0 0 0 0 0 0 0 0 0 -2M -3M 0 0
totalNonCurrentLiabilities 7M 8M 8M 0 0 0 0 0 0 0 0 0 2M 3M 0 0
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 -2M -3M 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 23M 25M 28M 9M 9M 6M 5M 5M 5M 0 12M 0 3M 6M 6M 5M
preferredStock 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
commonStock 7M 7M 5M 2M 2M 2M 1M 1M 1M 0 745 000 0 593 492 593 492 475 973 384 733
retainedEarnings -259M -253M -247M -243M -241M -233M -227M -227M -220M 0 -217M 0 -211M -205M -200M -182M
accumulatedOtherComprehensiveIncomeLoss -1M -1M -738 000 -926 000 -749 000 51M 51M 51M -825 877 0 51M 0 -621 557 -573 317 52M -648 065
othertotalStockholdersEquity 277M 273M 235M 235M 176M 175M 223M 0 0 219M 219M
totalStockholdersEquity 23M 26M 22M -7M -4M -4M -229 000 -229 000 3M 0 2M 0 8M 14M 6M 9M
totalEquity 23M 26M 22M -7M -4M -4M -229 000 -229 000 3M 0 2M 0 8M 14M 6M 9M
totalLiabilitiesAndStockholdersEquity 45M 51M 3M 5M 3M 4M 8M 0 0 11M 19M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 45M 51M 51M 3M 5M 3M 4M 4M 8M 0 14M 0 11M 19M 12M 15M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 2M 2M 3M 1 000 000 1 000 000 0 0 0 0 0 0 0 0 0 0 0
netDebt -367 000 -1M 661 000 -1M -3M -1M -4M -4M -7M 0 -13M 0 -8M -17M -9M -14M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-04-15 2024-03-29 2023-05-01 2022-05-16 2021-04-21
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 201 000 0 0 0 0
prepaids 92 000 299 000 465 000 2M 292 680
totalPayables 12M 2M 947 000 2M 3M
otherPayables 0 0 0 0 0
accruedExpenses 3M 187 000 3M 3M 2M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 265M 175M 167M 153M 192M
otherTotalStockholdersEquity 0 0 0 765 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2022 q4 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-19 2024-08-19 2024-03-31 2023-09-30 2023-09-29 2022-09-27 2022-05-17
acceptedDate 2025-11-13 17:01:14 2025-08-13 17:01:23 2025-04-15 16:33:07 2024-11-19 16:48:29 2024-08-19 16:30:27 2024-03-29 20:00:00 2024-03-29 14:15:41 2023-09-28 20:00:00 2023-09-29 08:01:40 2023-04-28 15:29:46 2022-09-27 16:30:48 2022-05-17 16:30:36 2022-05-16 06:04:17 2021-04-20 18:33:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 FY Q2 Q1 FY FY
netIncome -6M -2M -20M -3M -8M -6M -10M -4M -1499.304 -18M -6M -5M -17M -17M
depreciationAndAmortization 0 0 14 000 1 0 12 999 4000 1075 0.925 4000 942 1006 4126 8907
deferredIncomeTax -1M 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 0 719 000 2M 988 259 445 296 1M 304 237 270.763 735 000 122 856 98 836 314 650 325 523
changeInWorkingCapital -577 825 -416 000 7M -2M 564 2M -866 000 534 002 0 822 000 -3M 109 304 -2M -55 629
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0 0 0 0 0 0 0 -241 309 0
otherWorkingCapital -577 825 -416 000 7M -2M 564 2M -866 000 534 002 0 822 000 0 0 -2M -55 629
otherNonCashItems 6M -2M -2M 2M 3M -62 999 -7M -763 767 -3559.235 -5M -54 142 -82 362 242 503 -147 592
netCashProvidedByOperatingActivities -2M -3M -13M -1M -5M -4M -16M -3M -4786.851 -22M -9M -5M -19M -17M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 382 000 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 0 0 0 0
debtRepayment 2M -214 000 -336 000 669 000 -215 0 0 0 0
commonStockIssued -29 520 4M -133 000 7M 2M 0 0 0 12M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1647.803 -727 000 26 001 -1 -212 000 2M 1751.416 0 0
netCashUsedProvidedByFinancingActivities 2M 3M -442 999 8M 2M 2M 1751.416 0 12M
effectOfForexChangesOnCash -1654 4000 -4000 2000 -2000 -5 7000 2693 0.807 105 000 2404 44 375 -140 732 200 533
netChangeInCash -227 000 129 000 -1M -2M 3M 1M -9M -2M -3034.628 4M -9M 7M -5M 8M
cashAtEndOfPeriod 3M 3M 3M 2M 4M 1M 4M -1667.872 -3034.628 13M 8M 17M 9M 14M
cashAtBeginningOfPeriod 3M 3M 4M 4M 1M 3845 13M 2M 0 9M 17M 9M 14M 6M
operatingCashFlow -2M -3M -13M -1M -5M -4M -16M -3M -4786.851 -22M -9M -5M -19M -17M
capitalExpenditure -3.679 0 0 0 0 0 0 0 0 0 0 0 0 0
freeCashFlow -2M -3M -13M -1M -5M -4M -16M -3M -4786.851 -22M -9M -5M -19M -17M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-04-15 2024-03-29 2023-05-01 2022-05-16 2021-04-21
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 382 000 0 0 0 0
netDebtIssuance -855 000 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance -855 000 0 0 0 0
netStockIssuance 12M 7M 25M 14M 25M
netCommonStockIssuance 12M 7M 25M 14M 25M
commonStockIssuance 12M 7M 25M 14M 25M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 28 000 4000 94 000 0 27 500
netCashProvidedByFinancingActivities 11M 7M 25M 14M 25M
incomeTaxesPaid 0 0 0 0 0
interestPaid 143 000 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-12-16 21:30 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-12-08 08:00 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-12-08 08:00 ET
Akari Therapeutics published news for 2025 q3
SEC form 10
2025-11-13 22:01 ET
Akari Therapeutics reported for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-16 13:20 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-15 12:45 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-10-15 12:45 ET
Akari Therapeutics published news for 2025 q3
SEC form 8
2025-09-25 21:00 ET
Akari Therapeutics published news for 2025 q2
SEC form 8
2025-09-25 21:00 ET
Akari Therapeutics published news for 2025 q2
SEC form 8
2025-08-19 12:00 ET
Akari Therapeutics published news for 2025 q2
SEC form 8
2025-08-19 12:00 ET
Akari Therapeutics published news for 2025 q2
SEC form 10
2025-08-13 21:01 ET
Akari Therapeutics reported for 2025 q2
SEC form 8
2025-05-15 00:00 ET
Akari Therapeutics published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Akari Therapeutics published news for 2025 q1
SEC form 10
2025-05-14 20:51 ET
Akari Therapeutics reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Akari Therapeutics reported for 2025 q1
SEC form 8
2025-04-16 00:00 ET
Akari Therapeutics published news for 2025 q1
SEC form 8
2025-04-16 00:00 ET
Akari Therapeutics published news for 2025 q1
SEC form 10
2025-04-15 20:33 ET
Akari Therapeutics reported for 2024 q4
SEC form 10
2025-04-15 00:00 ET
Akari Therapeutics reported for 2024 q4
SEC form 8
2025-03-03 14:10 ET
Akari Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 14:10 ET
Akari Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 14:10 ET
Akari Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 14:10 ET
Akari Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 14:10 ET
Akari Therapeutics published news for 2024 q4
SEC form 10
2024-11-19 16:48 ET
Akari Therapeutics reported for 2024 q3
SEC form 10
2024-11-19 00:00 ET
Akari Therapeutics reported for 2024 q3
SEC form 10
2024-08-19 00:00 ET
Akari Therapeutics reported for 2024 q2
SEC form 8
2024-08-19 00:00 ET
Akari Therapeutics published news for 2024 q2
SEC form 8
2024-08-19 00:00 ET
Akari Therapeutics published news for 2024 q2
SEC form 10
2024-05-15 00:00 ET
Akari Therapeutics reported for 2024 q1
SEC form 8
2024-04-01 00:00 ET
Akari Therapeutics published news for 2024 q1
SEC form 8
2024-04-01 00:00 ET
Akari Therapeutics published news for 2024 q1
SEC form 10
2024-03-29 16:15 ET
Akari Therapeutics reported for 2023 q4
SEC form 10
2024-03-29 00:00 ET
Akari Therapeutics reported for 2023 q4
SEC form 6
2023-12-01 08:00 ET
Akari Therapeutics published news for 2023 q3
SEC form 6
2023-11-16 08:00 ET
Akari Therapeutics published news for 2023 q3
SEC form 6
2023-09-29 00:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-09-21 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-09-05 09:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-18 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-15 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-02 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-27 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-25 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-19 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-13 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-11 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-07 16:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-06 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-05 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-06-30 16:30 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-06-06 08:59 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-22 08:30 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-05 08:00 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-03 17:00 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-01 08:05 ET
Akari Therapeutics published news for 2023 q1
SEC form 20
2023-05-01 00:00 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-04-28 18:29 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-04-25 16:20 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-03-31 10:31 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-29 09:00 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-28 09:03 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 09:00 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-21 08:06 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-15 16:30 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-15 08:05 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-13 08:05 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2022-11-10 16:44 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-11-08 16:34 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-10-28 16:34 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-09-27 00:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-09-14 12:02 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-08-01 17:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-29 17:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-20 16:42 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-07 19:21 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-05 17:21 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-06-15 19:40 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 18:41 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-20 16:30 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-17 16:30 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 06:04 ET
Akari Therapeutics published news for 2022 q1
SEC form 20
2022-05-16 00:00 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-11 08:52 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 16:52 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-04-29 16:34 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-03-09 21:35 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 16:58 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 17:15 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-26 16:30 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-19 16:30 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-03 21:40 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2021-12-21 16:30 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-12-03 16:30 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-12-01 17:16 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-10-25 16:48 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-09-22 00:00 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-20 17:19 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-07 16:15 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-01 17:39 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-06-29 16:47 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-06-07 17:30 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:54 ET
Akari Therapeutics published news for 2021 q1
SEC form 20
2021-04-21 00:00 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 18:48 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 18:33 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-12 16:43 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-03-04 17:22 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:31 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2021-02-01 17:34 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2020-12-11 16:20 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-11 16:19 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-09 16:15 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-03 16:37 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-11-16 09:40 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-10-06 09:28 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 09:30 ET
Akari Therapeutics published news for 2020 q3